Literature DB >> 6353396

Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy.

R Stuart-Harris, R Buckman, I Starke, E Wiltshaw.   

Abstract

The use of cisplatin may be associated with severe nausea and vomiting. Two separate, randomized, double-blind trials, comparing the anti-emetic effect of chlorpromazine with placebo and chlorpromazine with droperidol, were conducted in patients receiving cisplatin for ovarian cancer. Chlorpromazine was statistically superior to placebo in the control of nausea and vomiting in those patients treated with chlorpromazine had significantly less nausea than with droperidol, but there were no other significant differences between chlorpromazine and droperidol. Toxicities of chlorpromazine and droperidol were similar. Chlorpromazine shows useful activity against cisplatin nausea and vomiting.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6353396      PMCID: PMC2417595          DOI: 10.1136/pgmj.59.694.500

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  3 in total

1.  Droperidol prevents nausea and vomiting from cis-platinum.

Authors:  B Grossman; L S Lessin; P Cohen
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

2.  A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotheray with cis-platinum.

Authors:  A J Jacobs; G Deppe; C J Cohen
Journal:  Gynecol Oncol       Date:  1980-08       Impact factor: 5.482

Review 3.  The control of chemotherapy-induced emesis.

Authors:  L J Seigel; D L Longo
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

  3 in total
  4 in total

Review 1.  Droperidol for treatment of nausea and vomiting in palliative care patients.

Authors:  Jemma Storrar; Morwenna Hitchens; Tracey Platt; Saskie Dorman
Journal:  Cochrane Database Syst Rev       Date:  2014-11-27

2.  Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.

Authors:  Jørn Herrstedt; Yvonne Summers; Gedske Daugaard; Thomas B Christensen; Karin Holmskov; Paul D Taylor; Gabriel M Fox; Alexander Molassiotis
Journal:  Support Care Cancer       Date:  2017-08-11       Impact factor: 3.603

Review 3.  [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors:  A Du Bois
Journal:  Med Klin (Munich)       Date:  1998-01

4.  Influence of dosing times on cisplatin-induced peripheral neuropathy in rats.

Authors:  Yoshihiro Seto; Fumiyasu Okazaki; Keiji Horikawa; Jing Zhang; Hitoshi Sasaki; Hideto To
Journal:  BMC Cancer       Date:  2016-09-27       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.